Amit Sachdev compensation by year
Vertex Pharmaceuticals Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $700,000 |
| Bonus | $0 |
| Stock awards | $4,900,522 |
| Option awards | $0 |
| Non-equity incentive | $1,155,420 |
| Pension and deferred compensation | $0 |
| All other | $21,301 |
| Total | $6,777,243 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vertex Pharmaceuticals Inc DEF 14A filed April 2, 2026, accession 0000875320-26-000153, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 7,866 | $3,566,130 | — |
| RSU | 7,114 | $3,225,203 | — |
| RSU | 6,212 | $2,816,272 | — |
| RSU | 6,211 | $2,815,819 | — |
| RSU | 4,744 | $2,150,740 | — |
| RSU | 4,743 | $2,150,286 | — |
| RSU | 3,883 | $1,760,397 | — |
| RSU | 2,622 | $1,188,710 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Vertex Pharmaceuticals Inc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 2, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-21 | Grant or award | — | 8,251 | $0.00 | 66,512 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Vertex Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Reshma Kewalramani | Chief Executive Officer and President | $21,144,261 |
| Stuart Arbuckle | Former Executive Vice President, Chief Operating Officer | $9,996,347 |
| Charles Wagner | Executive Vice President, Chief Operating and Financial Officer | $8,241,809 |
| Nia Tatsis | Executive Vice President, Chief Regulatory and Quality Officer | $6,974,920 |
| Amit Sachdev · this page | Executive Vice President, Chief Patient and External Affairs Officer | $6,777,243 |
| Carmen Bozic | Executive Vice President, Chief Medical Officer | $6,646,321 |
The full Vertex Pharmaceuticals compensation record
free company briefThis page is one person within Vertex Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Vertex Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vertex Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat